Coagulation Analyzers Market Size, Report, Share & Growth Trends 2030

Name: Coagulation Analyzers Market Size, Report, Share & Growth Trends 2030
Creator: Mordor Intelligence
License: https://www.mordorintelligence.com/privacy-policy

Coagulation Analyzers Market Size and Share

Market Overview

Study Period	2019 - 2030
Market Size (2025)	USD 4.49 Billion
Market Size (2030)	USD 5.33 Billion
Growth Rate (2025 - 2030)	10.21% CAGR
Fastest Growing Market	Asia Pacific
Largest Market	North America
Market Concentration	Medium
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Coagulation Analyzers Market (2025 - 2030) — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Coagulation Analyzers Market Analysis by Mordor Intelligence

The coagulation analyzers market size stands at USD 4.49 billion in 2025 and is forecast to touch USD 5.33 billion by 2030, advancing at a 6.2% CAGR. Growth stems from the shift toward real-time viscoelastic platforms, tighter quality regulations, and wider adoption of AI-guided dosing that trims adverse events by 30% compared with conventional monitoring. Viscoelastic analyzers deliver complete clotting profiles within minutes, enabling surgical teams to save blood products and shorten operating room time. At the same time, Class II re-classification in May 2025 has lowered regulatory barriers, encouraging regional manufacturers to enter the coagulation analyzers market and diversify supply. Intensifying M&A activity—such as Werfen’s purchase of Accriva and the long-term Siemens–Sysmex OEM pact—signals a race to secure reagent lines and embedded analytics.

Key Report Takeaways

By product, systems and analyzers led with 60.2% revenue share in 2024; point-of-care analyzers are projected to ramp up at an 11.7% CAGR to 2030.
By test type, PT/INR accounted for 30.6% of the coagulation analyzers market size in 2024, while D-Dimer assays are on course for a 12.4% CAGR through 2030.
By technology, optical methods held 43.1% of the coagulation analyzers market share in 2024; viscoelastic/magnetic technologies are forecast to rise at 14.4% CAGR between 2025 and 2030.
By modality, hospital-based central laboratories captured 54.4% share of the coagulation analyzers market size in 2024; point-of-care devices are poised for a 15.9% CAGR through 2030.
By geography, North America led with a 43.5% share of the coagulation analyzers market in 2024, while Asia-Pacific is set to register the fastest growth at an 16.1% CAGR between 2025 and 2030.

Global Coagulation Analyzers Market Trends and Insights

Drivers Impact Analysis

Driver	( ~ ) % Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
Growing prevalence of bleeding & thrombotic disorders	+1.80%	Global, higher in aging populations	Long term (≥ 4 years)
Aging population & chronic-disease burden	+1.50%	Developed markets	Long term (≥ 4 years)
Laboratory automation & high-throughput analyzers	+1.20%	North America & Europe	Medium term (2–4 years)
Rise of point-of-care clotting tests	+1.00%	Emergency and surgical settings worldwide	Medium term (2–4 years)
Rapid uptake of viscoelastic testing	+0.80%	North America & Europe	Short term (≤ 2 years)
AI-driven, patient-specific algorithms	+0.60%	Early adoption in North America & Europe	Long term (≥ 4 years)
Source: Mordor Intelligence

Growing Prevalence of Bleeding & Thrombotic Disorders

Hemophilia affects 273,000 diagnosed individuals, with an additional 563,000 likely undiagnosed, elevating demand for precise coagulation monitoring.^{[1]James O’Donnell, “Global Hemophilia Burden,” frontiersin.org}Von Willebrand disease remains the most common hereditary bleeding disorder, and 72–94% of patients experience clinical bleeding episodes that benefit from rapid laboratory confirmation. New therapies such as fitusiran, cleared by the FDA in March 2025, require antithrombin assays, further broadening the coagulation analyzers market.

Ageing Population & Chronic-Disease Burden

Surging atrial fibrillation prevalence in seniors heightens long-term anticoagulation needs. Thromboelastography demonstrates superior bleed-prediction accuracy versus conventional tests in elderly cohorts. Direct oral anticoagulant uptake, led by apixaban, underlines a market pivot toward newer drugs that still warrant episodic coagulation checks.^{[2]Wei Zhang, “Carbon-Nanotube Fluorescent Clot Sensor,” mdpi.com}

Laboratory Automation & High-Throughput Analyzers

Platforms such as Sysmex CS-5100 process up to 402 tests per hour with ≤3% CV, meeting hospitals’ drive for turnaround time under 60 minutes. Siemens’ Atellica COAG 360 posts 98% operator satisfaction, highlighting usability gains vital for the coagulation analyzers market.

Rise of Point-of-Care Clotting Tests

Handheld INR meters deliver lab-equivalent accuracy, fostering home-based therapy adjustment and unclogging outpatient clinics.^{[3]Kenneth Uhl, “Handheld INR Accuracy,” mayoclinicproceedings.org} The April 2024 TEG 6s HN cartridge brings viscoelastic insight to heparinized cardiac cases, trimming transfusion rates

Restraints Impact Analysis

Restraint	( ~ ) % Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
High capital & reagent costs	-1.20%	Emerging markets worldwide	Medium term (2–4 years)
Limited adoption in low-income nations	-0.80%	Sub-Saharan Africa & parts of Asia	Long term (≥ 4 years)
Reagent-supply shocks from porcine heparin & IVDR	-0.60%	Global supply chains	Short term (≤ 2 years)
Emerging non-invasive biomarkers	-0.40%	North America & Europe	Long term (≥ 4 years)
Source: Mordor Intelligence

Segment Analysis

By Product: Automation Drives Systems Dominance

Systems and analyzers held a 60.2% share of the coagulation analyzers market in 2024 as laboratories prioritized walk-away automation to control rising test volumes without adding staff. Point-of-care units posted the quickest uptake, supported by the TEG 6s clearance that expanded viscoelastic testing into cardiac theaters. Robust throughput—402 tests per hour on high-end models—reduces bottlenecks during morning phlebotomy peaks, cementing vendor lock-in through consumable contracts.

Consumables form the recurring backbone of the coagulation analyzers market. Reagent integrity demands have sharpened since porcine-heparin contamination alerts triggered global recalls. In response, OEM alliances such as the 2024 Siemens–Sysmex pact guarantee steady reagent pipelines and forward-integration of AI-enabled QC packs. Calibration materials also benefit from stricter CLIA precision goals, nudging laboratories toward premium controls with validated lot-to-lot consistency.

Coagulation Analyzers Market: Market Share by Product — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Test Type: D-Dimer Surges Amid Thrombosis Focus

PT/INR continues to anchor chronic warfarin surveillance, capturing 30.6% of coagulation analyzers market size in 2024. Nonetheless, clinicians increasingly prefer anti-Xa assays for low-molecular-weight heparin, reflecting therapy migration. D-Dimer, meanwhile, is posting the fastest 12.4% CAGR as emergency departments rely on it to triage venous thromboembolism and monitor post-COVID coagulopathy.

Fibrinogen and platelet-function panels round out the catalog, supporting trauma protocols and antiplatelet agent adjustment. Global hemostasis applications—TEG and ROTEM—are expanding beyond operating theaters into intensive-care settings, fueled by the May 2025 Class II reclassification that trimmed time-to-market for new cartridges.

By Technology: Viscoelastic Methods Challenge Optical Dominance

Optical analyzers retained a 43.1% coagulation analyzers market share in 2024 thanks to deep installed bases and mature QC frameworks. Even so, viscoelastic and magnetic modalities are scheduled for a 14.4% CAGR as perioperative teams seek whole-blood insight that standard photometric curves cannot provide. Portable viscoelastic units now fit on anesthesia carts, tightening feedback loops during liver resections.

Electrochemical chips and smartphone-linked optical sensors are moving from proof-of-concept to pilot deployments in outpatient anticoagulation clinics. Researchers report successful clot-time tracking via carbon-nanotube fluorescence, hinting at low-cost disposables that could open the coagulation analyzers market to community pharmacies.

Coagulation Analyzers Market: Market Share by Technology — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Modality: Point-of-Care Gains Ground

Central laboratories still dominate hospital contracts because they deliver broad menus and bulk reagent discounts. Yet point-of-care models logged a 15.9% CAGR as caregivers push testing to bedsides for trauma, transplant, and obstetric cases, where 10-minute answers alter surgical decisions.

Home-care self-testing represents the next frontier. Pocket INR meters paired with cloud dashboards show stable time-in-therapeutic range and fewer clinic visits, aligning with payer incentives for remote management. However, reimbursement clarity and operator-training thresholds vary, limiting near-term rollouts outside high-income countries.

By End User: Home-Care Emerges as Growth Leader

Hospitals accounted for 54.4% of revenue in 2024, reflecting comprehensive in-house need across emergency, surgery, and specialized coagulation clinics. Clinical reference labs handle esoteric factor analyses and genetic panels that smaller hospitals outsource.

Home-care lines, projected to grow 15.9% annually, benefit from population aging and digital literacy improvements. Wearable biosensors under development promise continuous coagulation trendlines rather than spot checks, potentially shrinking readmission risk in heart-failure patients receiving dual antithrombotic therapy.

Geography Analysis

North America leads the coagulation analyzers market, supported by well-funded hospitals, rapid AI adoption, and favorable reimbursement frameworks. The March 2025 FDA approval of fitusiran with a companion antithrombin assay illustrates how therapeutic innovation immediately triggers diagnostic demand. Canada’s single-payer model drives nationwide INR management networks, while Mexico’s emerging private hospital chains are investing in point-of-care devices to shorten emergency room stay times.

Asia Pacific is the fastest-advancing region, reflecting swift infrastructure upgrades and growing senior populations that require routine coagulation surveillance. China’s role as the world’s largest heparin supplier offers cost advantages but also vulnerability to raw-material shocks. Japan’s stringent device review process ensures high laboratory standards, whereas recent regulatory reforms in India have opened pathways for domestic manufacturing of mid-throughput analyzers. Sysmex reported double-digit regional sales growth in Q1 2025, underscoring unmet demand for reagents and controls.

Europe balances strong scientific capability with the added burden of IVDR compliance. Germany, France, and the United Kingdom operate expansive reference-lab networks that already meet most new documentation mandates, but smaller centers face costly validation work. Supply concerns around porcine-derived reagents have sparked pilot studies into bovine alternatives, while NHS blood shortage episodes in England spotlight the importance of viscoelastic testing for judicious transfusion practice.

Coagulation Analyzers Market CAGR (%), Growth Rate by Region — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The coagulation analyzers market exhibits moderate consolidation: the top five vendors control an estimated two-thirds of global revenue, yet technological churn allows nimble entrants to secure niche footholds. Siemens Healthineers and Sysmex extend a 25-year alliance through a fresh OEM deal that bundles instruments and reagents under shared service contracts. Roche strengthens its high-throughput position with Factor Xa tests tailored to direct oral anticoagulant monitoring.

Werfen deepened its point-of-care reach by acquiring Accriva Diagnostics, gaining Hemochron and VerifyNow to complement its laboratory GEM line. Haemonetics focuses on viscoelastic leadership, adding heparin-neutralized cartridges to cover cardiovascular surgeries. Across the tier-two scene, start-ups leverage AI to convert raw clot curves into predictive bleed-risk scores, pitching cloud APIs that fit alongside legacy LIS systems.

Competitive pressure is likely to intensify as pharmaceutical firms seek companion diagnostics synchronized with next-generation anticoagulants. The May 2025 easing of U.S. regulatory classification for viscoelastic systems also lowers capital hurdles for local manufacturers, potentially fragmenting share in price-sensitive segments.

Coagulation Analyzers Industry Leaders

F. Hoffmann-La Roche Ltd
Siemens Healthineers AG
Sysmex Corporation
Beckman Coulter (Danaher)
Werfen (Instrumentation Laboratory)
*Disclaimer: Major Players sorted in no particular order

Coagulation Analyzers Market Concentration — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Need More Details on Market Players and Competitors?

Download PDF

Recent Industry Developments

May 2025: The FDA approved Qfitlia (fitusiran), which requires INNOVANCE Antithrombin monitoring and has been shown to cut annual bleeding episodes by 71–73% in pivotal trials.
April 2024: Haemonetics gained 510(k) clearance for the TEG 6s Global Hemostasis-HN cartridge aimed at heparinized cardiac cases,
February 2024: Siemens Healthineers and Sysmex renewed a global OEM agreement covering hemostasis instruments and reagents.
February 2024: Werfen completed the acquisition of Accriva Diagnostics, reinforcing its hospital point-of-care coagulation lineup.

Table of Contents for Coagulation Analyzers Industry Report

1. Introduction

1.1 Study Assumptions & Market Definition
1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Growing Prevalence Of Bleeding & Thrombotic Disorders
- 4.2.2 Ageing Population & Chronic-Disease Burden
- 4.2.3 Laboratory Automation & High-Throughput Analyzers
- 4.2.4 Rise Of Point-Of-Care Clotting Tests
- 4.2.5 Rapid Uptake Of Viscoelastic Testing (TEG/ROTEM)
- 4.2.6 AI-Driven, Patient-Specific Anticoagulation Algorithms
4.3 Market Restraints
- 4.3.1 High Capital & Reagent Costs
- 4.3.2 Limited Adoption In Low-Income Nations
- 4.3.3 Reagent-Supply Shocks From Porcine-Heparin & IVDR Changes
- 4.3.4 Emerging Non-Invasive Hemostasis Biomarkers
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
- 4.7.1 Threat of New Entrants
- 4.7.2 Bargaining Power of Buyers/Consumers
- 4.7.3 Bargaining Power of Suppliers
- 4.7.4 Threat of Substitute Products
- 4.7.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

5.1 By Product
- 5.1.1 Systems / Analyzers
- 5.1.1.1 High-throughput Lab Analyzers
- 5.1.1.2 Mid-throughput Lab Analyzers
- 5.1.1.3 Point-of-Care Analyzers
- 5.1.2 Consumables
- 5.1.2.1 Reagents & Assays
- 5.1.2.2 Calibrators & Controls
- 5.1.2.3 Others
5.2 By Test Type
- 5.2.1 Prothrombin Time (PT/INR)
- 5.2.2 Activated Partial Thromboplastin Time (aPTT)
- 5.2.3 D-Dimer
- 5.2.4 Fibrinogen
- 5.2.5 Platelet Function
- 5.2.6 Anti-Factor Xa
- 5.2.7 Global Hemostasis (TEG/ROTEM)
- 5.2.8 Other Tests
5.3 By Technology
- 5.3.1 Optical
- 5.3.2 Mechanical
- 5.3.3 Electrochemical
- 5.3.4 Magnetic / Viscoelastic
- 5.3.5 Other Technologies
5.4 By Modality
- 5.4.1 Central-Laboratory Platforms
- 5.4.2 Point-of-Care Devices
- 5.4.3 Self-Testing / Home-care Devices
5.5 By End User
- 5.5.1 Hospitals
- 5.5.2 Clinical & Reference Laboratories
- 5.5.3 Ambulatory Surgical Centers
- 5.5.4 Home-care Settings
- 5.5.5 Others
5.6 Geography
- 5.6.1 North America
- 5.6.1.1 United States
- 5.6.1.2 Canada
- 5.6.1.3 Mexico
- 5.6.2 Europe
- 5.6.2.1 Germany
- 5.6.2.2 United Kingdom
- 5.6.2.3 France
- 5.6.2.4 Italy
- 5.6.2.5 Spain
- 5.6.2.6 Rest of Europe
- 5.6.3 Asia Pacific
- 5.6.3.1 China
- 5.6.3.2 Japan
- 5.6.3.3 India
- 5.6.3.4 South Korea
- 5.6.3.5 Australia
- 5.6.3.6 Rest of Asia Pacific
- 5.6.4 Middle East & Africa
- 5.6.4.1 GCC
- 5.6.4.2 South Africa
- 5.6.4.3 Rest of Middle East & Africa
- 5.6.5 South America
- 5.6.5.1 Brazil
- 5.6.5.2 Argentina
- 5.6.5.3 Rest of South America

6. Competitive Landscape

6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
- 6.3.1 Siemens Healthineers
- 6.3.2 Sysmex Corporation
- 6.3.3 F. Hoffmann-La Roche Ltd
- 6.3.4 Beckman Coulter (Danaher)
- 6.3.5 Werfen (Instrumentation Laboratory)
- 6.3.6 Diagnostica Stago SAS
- 6.3.7 Abbott Laboratories
- 6.3.8 Thermo Fisher Scientific
- 6.3.9 Horiba Ltd
- 6.3.10 Helena Laboratories
- 6.3.11 Sysmex America
- 6.3.12 Trivitron Healthcare
- 6.3.13 Eurolyser Diagnostica GmbH
- 6.3.14 Haemonetics Corporation
- 6.3.15 Meril Life Sciences
- 6.3.16 Nihon Kohden Corporation
- 6.3.17 Tosoh Corporation
- 6.3.18 Stago UK
- 6.3.19 Medirox AB
- 6.3.20 Rayto Life and Analytical Sciences

7. Market Opportunities & Future Outlook

7.1 White-space & Unmet-Need Assessment

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections

Get Price Break-up Now

Global Coagulation Analyzers Market Report Scope

As per the scope of this report, coagulation analyzers are used for detecting the presence of blood clots in the blood vessels. These analyzers measure coagulation pathway speed as well as thrombolin and thromboplastin levels in a few minutes. A coagulation analyzer system also has built-in quality control and security lockout protocols to ensure safe and secure use, as it is used on sensitive information about patients' health. The Coagulation Analyzers Market is segmented by Product (Analyzers (Clinical Laboratory Analyzers, and Point of Care Analyzers), and Consumables), By Test Type (Fibrinogen Testing, D-Dimer Testing, Platelet Function Tests and Other Coagulation Tests), Technology (Optical, Mechanical, Electrochemical, and Others), End-User (Hospitals, Diagnostic Centers and Others) and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product	Systems / Analyzers	High-throughput Lab Analyzers
		Mid-throughput Lab Analyzers
		Point-of-Care Analyzers

	Consumables	Reagents & Assays
		Calibrators & Controls
		Others
By Test Type	Prothrombin Time (PT/INR)
	Activated Partial Thromboplastin Time (aPTT)
	D-Dimer
	Fibrinogen
	Platelet Function
	Anti-Factor Xa
	Global Hemostasis (TEG/ROTEM)
	Other Tests
By Technology	Optical
	Mechanical
	Electrochemical
	Magnetic / Viscoelastic
	Other Technologies
By Modality	Central-Laboratory Platforms
	Point-of-Care Devices
	Self-Testing / Home-care Devices
By End User	Hospitals
	Clinical & Reference Laboratories
	Ambulatory Surgical Centers
	Home-care Settings
	Others

Geography	North America	United States
		Canada
		Mexico

	Europe	Germany
		United Kingdom
		France
		Italy
		Spain
		Rest of Europe

	Asia Pacific	China
		Japan
		India
		South Korea
		Australia
		Rest of Asia Pacific

	Middle East & Africa	GCC
		South Africa
		Rest of Middle East & Africa

	South America	Brazil
		Argentina
		Rest of South America

By Product

Systems / Analyzers	High-throughput Lab Analyzers
	Mid-throughput Lab Analyzers
	Point-of-Care Analyzers
Consumables	Reagents & Assays
	Calibrators & Controls
	Others

By Test Type

Prothrombin Time (PT/INR)

Activated Partial Thromboplastin Time (aPTT)

D-Dimer

Fibrinogen

Platelet Function

Anti-Factor Xa

Global Hemostasis (TEG/ROTEM)

Other Tests

By Technology

Optical

Mechanical

Electrochemical

Magnetic / Viscoelastic

Other Technologies

By Modality

Central-Laboratory Platforms

Point-of-Care Devices

Self-Testing / Home-care Devices

By End User

Hospitals

Clinical & Reference Laboratories

Ambulatory Surgical Centers

Home-care Settings

Others

Geography

North America	United States
	Canada
	Mexico
Europe	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe
Asia Pacific	China
	Japan
	India
	South Korea
	Australia
	Rest of Asia Pacific
Middle East & Africa	GCC
	South Africa
	Rest of Middle East & Africa
South America	Brazil
	Argentina
	Rest of South America

Need A Different Region or Segment?

Customize Now

Key Questions Answered in the Report

What is the current size and growth outlook for the global coagulation analyzers market?

The market is valued at USD 4.49 billion in 2025 and is projected to reach USD 5.33 billion by 2030, reflecting a 6.2% CAGR.

Which product category is expanding the quickest?

Point-of-care analyzers are growing at an 11.7% CAGR as hospitals and emergency units prioritize bedside coagulation results.

Why is viscoelastic testing (TEG/ROTEM) gaining rapid adoption?

These platforms deliver real-time, whole-blood clotting profiles within minutes, improving transfusion decisions and benefiting from a May 2025 Class II re-classification that lowered regulatory hurdles.

Which geographic region is forecast to grow the fastest?

Asia Pacific leads with a 16.1% CAGR due to aging populations, infrastructure upgrades, and rising chronic-disease burdens.

Page last updated on: June 29, 2025